

# Resource Summary Report

Generated by [dkNET](#) on Sep 19, 2026

## Rabbit Anti-Her4 / ErbB4 Monoclonal Antibody, Unconjugated, Clone 111B2

RRID:AB\_2099883

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 4795, RRID:AB\_2099883

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2099883](http://antibodyregistry.org/AB_2099883)

**Proper Citation:** Cell Signaling Technology Cat# 4795, RRID:AB\_2099883

**Target Antigen:** Her4 / ErbB4

**Host Organism:** rabbit

**Clonality:** monoclonal

**Comments:** Applications: W, IP. Consolidation on 10/2018: AB\_10698607, AB\_2099883.

**Antibody Name:** Rabbit Anti-Her4 / ErbB4 Monoclonal Antibody, Unconjugated, Clone 111B2

**Description:** This monoclonal targets Her4 / ErbB4

**Target Organism:** human

**Clone ID:** Clone 111B2

**Antibody ID:** AB\_2099883

**Vendor:** Cell Signaling Technology

**Catalog Number:** 4795

**Record Creation Time:** 20231110T044857+0000

**Record Last Update:** 20260831T203617+0000

---

### Ratings and Alerts

No rating or validation information has been found for Rabbit Anti-Her4 / ErbB4 Monoclonal Antibody, Unconjugated, Clone 111B2.

No alerts have been found for Rabbit Anti-Her4 / ErbB4 Monoclonal Antibody, Unconjugated, Clone 111B2.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 14 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene, 45(31), 3244.

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Li C, et al. (2025) Liver-breast communication of adipocyte-oriented exosomes drives primary mammary cancer progression. Cell metabolism.

Trenker R, et al. (2024) Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation. eLife, 12.

Huang J, et al. (2024) NRG1-ErbB4 signaling in the medial amygdala controls mating motivation in adult male mice. Cell reports, 43(3), 113905.

Albert V, et al. (2024) HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. International journal of molecular sciences, 25(13).

Bahnassy S, et al. (2023) Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer. Endocrinology, 164(12).

Bahnassy S, et al. (2023) Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer. bioRxiv : the preprint server for biology.

Wurm AA, et al. (2023) Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity. Cell reports. Medicine, 4(10), 101200.

Spahic H, et al. (2022) Dysregulation of ErbB4 Signaling Pathway in the Dorsal Hippocampus after Neonatal Hypoxia-Ischemia and Late Deficits in PV+ Interneurons, Synaptic Plasticity and Working Memory. *International journal of molecular sciences*, 24(1).

De Bacco F, et al. (2021) ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. *Cell reports*, 36(4), 109455.

Iniguez AB, et al. (2018) Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. *Cancer cell*, 34(6), 922.

Cooper MA, et al. (2014) Ablation of ErbB4 from excitatory neurons leads to reduced dendritic spine density in mouse prefrontal cortex. *The Journal of comparative neurology*, 522(14), 3351.